AI Article Synopsis
- The study aimed to compare the anesthetic effects of two forms of remimazolam (tositlate and besylate) in patients undergoing daytime hysteroscopic surgery.
- Fifty patients were randomly divided into two groups to evaluate differences in induction doses and various anesthesia-related outcomes.
- Results showed no significant differences between the two groups in terms of anesthesia induction, recovery time, and adverse effects, indicating both forms have similar anesthetic effects.
Article Abstract
Objective: The purpose of this study is to observe whether there is a difference in the anesthetic effect of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery, so as to provide reference for clinical application.
Methods: Fifty patients, aged 18-65 years, ASA I-II, scheduled for hysteroscopy under total intravenous anesthesia were selected. The patients were randomly divided into two groups (n = 25): remimazolam tosilate group (group T) and remimazolam besylate group ( group R). The main observation index was the induction dose of remimazolam; secondary observation indicators were sleep time, anesthesia maintenance time, recovery time, induction maintenance dose of alfentanil, maintenance dose of remimazolam, and incidence of adverse events during anesthesia ( hypertension, hypotension, bradycardia, tachycardia).
Results: There was no significant difference in anesthesia induction dose, recovery time, sleep time, anesthesia maintenance time, and incidence of adverse events during anesthesia ( body movement, cough, hypertension, hypotension, bradycardia, tachycardia) between the two groups (P > 0.05).
Conclusion: There was no significant difference in the anesthetic effect of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery.
Clinical Trial Registration: Chinese Clinical Trial Registry, ChiCTR2400081688.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515782 | PMC |
| http://dx.doi.org/10.1186/s12871-024-02773-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Procedural sedative effect of remimazolam in ICU patients on invasive mechanical ventilation: a randomised, prospective study.
Ann Intensive Care
January 2025
Department of Intensive Care Unit, Yanbian University Hospital, No. 1327, Juzi Street, Xinxing Street, Yanji, 136200, Jilin, China.
Background: Invasive procedures and environmental factors in the intensive care unit (ICU) may cause anxiety and discomfort in patients, who often require sedation therapy. The aim of this study was to assess the safety of remimazolam tosilate for procedural sedation in ICU patients receiving mechanical ventilation following endotracheal intubation. Eighty patients from a single centre were randomly assigned to either the propofol group or the remimazolam group.
View Article and Find Full Text PDFSafety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial.
Anaesthesia
November 2024
Department of Anaesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction: Remimazolam is an ultra-short-acting benzodiazepine sedative drug. This study aimed to compare the efficacy and safety of remimazolam with propofol for induction and maintenance of general anaesthesia in children undergoing elective surgery.
Methods: Children (aged 3-6 y, ASA physical status 1 or 2, BMI 14-25 kg.
Efficacy and safety of remimazolam tosilate in anesthesia for short otolaryngology surgery.
BMC Anesthesiol
November 2024
Department of Anesthesiology, the Second Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou, China.
Background: Remimazolam tosilate represents the novel ultrashort-acting benzodiazepine drug. This work focused on exploring whether remimazolam tosilate was effective and safe in anesthesia for short otolaryngology surgery in adults, and optimize its medication regimen, thus providing a theoretical basis for its widespread clinical application.
Methods: The present unicentric, double-blind, randomized controlled study enrolled altogether 85 otolaryngology surgery patients aged 18-60 years, and they were divided as remimazolam (RM, 42 cases) or midazolam (MD, 43 cases) group.
Comparison of the anesthetic effects of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery.
BMC Anesthesiol
October 2024
Department of Anesthesiology, Weifang People's Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang, 261041, China.
Article Synopsis
- The study aimed to compare the anesthetic effects of two forms of remimazolam (tositlate and besylate) in patients undergoing daytime hysteroscopic surgery.
- Fifty patients were randomly divided into two groups to evaluate differences in induction doses and various anesthesia-related outcomes.
- Results showed no significant differences between the two groups in terms of anesthesia induction, recovery time, and adverse effects, indicating both forms have similar anesthetic effects.
The efficacy and safety of remimazolam tosilate compared with propofol for endoscopic retrograde cholangiopancreatography under monitored anesthesia care: A single-center randomized controlled clinical trial.
Heliyon
October 2024
Department of Anesthesiology and Pain Medicine, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- Remimazolam tosilate, an ultra-short-acting benzodiazepine, was tested for its efficacy and safety in endoscopic retrograde cholangiopancreatography (ERCP) against propofol in a randomized controlled trial.
- The study found that remimazolam achieved a 100% success rate for ERCP completion, while propofol had a 96.1% success rate, indicating non-inferior performance for remimazolam.
- Additionally, remimazolam had lower incidents of adverse effects (like respiratory depression and hypotension) compared to propofol, though it had higher instances of gastrointestinal movements and injections pain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!